"This partnership is a strategic alliance between Gustave Roussy and LXRepair to address a real medical need. For LXRepair, it is a new step towards the adoption of our technology by oncologists and the validation of clinical biomarkers, beyond the breast and prostate cancer indications which are already in the clinical validation phase, and for which the launch of the Safer RAD-LX kit is planned for 2024," concludes Stéphane Altaba, chief executive officer of LXRepair
About LXRepair
LXREPAIR is a biotech company developing in vitro diagnostic (IVD) assays to predict cancer therapy outcomes. Its innovative assays are based on functional signatures of DNA repair biomarkers that can be detected on a biochip, from a blood sample or a tumor biopsy. In contrast to the genomic approach, the functional approach captures the actual activity DNA repair mechanisms. This approach makes LXRepair's assays more relevant and actionable than other non-functional DNA repair assays. This diagnostic information will enable the oncologist to personalize the patient's radiation or chemotherapy treatment.
About Gustave Roussy
Ranked first in Europe and fifth in the world in the fight against cancer, Gustave Roussy is a global center of expertise entirely dedicated to cancer patients. The Institute is a founding pillar of the Paris Saclay Cancer Cluster. A source of therapeutic innovations and diagnostic advances, the Institute treats nearly 50,000 patients each year and develops an integrated approach between research, care and teaching.
Back to HCB News
